Electra Therapeutics (ETRA) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
4D Molecular Therapeutics is the larger company by market cap ($576.8 million vs $509.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETRA | FDMT |
|---|---|---|
| Share price | $8.11 | $10.23 |
| Market cap | $509.85M | $576.76M |
| 1-day change | -9.28% | -4.57% |
| YTD return | — | +36.40% |
| 1-year return | — | -5.63% |
| 5-year return | — | -53.61% |
| EPS (TTM) | $-35.94 | $-2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $85.21M |
| Revenue growth (YoY) | — | +230194.59% |
| Net income (latest FY) | — | $-140.11M |
| Operating margin | — | -187.24% |
| Net margin | — | -164.43% |
| 52-week high | $15.50 | $16.93 |
| 52-week low | $6.87 | $6.96 |
| Distance from 52-week high | -47.68% | -39.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +309.37% | +174.58% |
| Average volume | 559.28K | 967.00K |
| Shares outstanding | 62.87M | 56.38M |
| Employees | 46 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
ETRA vs FDMT FAQ
Which is bigger, Electra Therapeutics or 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $576.76M compared with $509.85M for Electra Therapeutics (ETRA).
Are Electra Therapeutics and 4D Molecular Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.